Krystal Biotech, Inc. (NASDAQ: KRYS) FY2025 revenue ~$380-440M (+80-110%) with adj. EPS ~$4.50-5.40 reflecting continued post-May 2023 Vyjuvek FDA approval ~$380-440M aggregate Vyjuvek Topical Gene Therapy revenue (~$350-410M aggregate US Vyjuvek + ~$30-35M aggregate ex-US launches) under continued Co-Founder + CEO Krish Krishnan since 2017 (~8-year founding tenure as Krystal Biotech CEO). One of the largest US specialty commercial-stage gene therapy biotech companies. Founded April 2016 as Krystal Biotech by Krish Krishnan + Suma Krishnan in Pittsburgh Pennsylvania (~9-year heritage; selected pioneer Topical Gene Therapy using HSV-1 vector platform); selected post-September 2017 NASDAQ IPO ($32M IPO proceeds); selected post-2017-2025 ~$1.2B+ cumulative equity raises; selected post-May 2023 Vyjuvek FDA approval (1st FDA-approved topical gene therapy + 1st FDA-approved DEB treatment); selected post-April 2024 EU EMA Vyjuvek approval; selected post-2025 Japan PMDA Vyjuvek approval expected. Headquartered in Pittsburgh Pennsylvania; ~400-450 employees globally with ~15-20% Krish + Suma Krishnan + Foundation Asset Management + institutional ownership concentration. One primary business: commercial-stage gene therapy biotech ~100%. Structure: Vyjuvek Topical Gene Therapy ~100% ($380-440M). Geographic mix: US ~92%+ + EU + Japan + Korea + international ~8%. Vyjuvek Topical Gene Therapy pipeline (~$380-440M revenue + 1st-in-class): ~$380-440M aggregate Vyjuvek revenue (~100% revenue mix); selected primary post-May 2023 FDA approval (1st FDA-approved topical gene therapy + 1st FDA-approved DEB treatment); selected ~3,000-3,500+ US DEB patient addressable population; selected ~$0.5-1.0M annual cost per DEB patient; selected ~50-65% US Vyjuvek penetration rate; selected post-April 2024 EU EMA approval; selected post-2025 Japan PMDA approval expected. KB407 + KB408 + KB801 + Pipeline + Ex-US Launches: selected continued post-2024 KB407 (CF Phase 1) + KB408 (AATD Phase 1) + KB801 (Neurotrophic Keratitis Phase 1/2) + KB104 (Netherton Syndrome Phase 1/2) + KB707 (immunotherapy oncology Phase 1); selected Europe + Japan + Korea + Brazil + international Vyjuvek launches; selected Vyjuvek Pediatric label expansion. Co-Founder + CEO Krish Krishnan since 2017 (~8-year founding tenure; co-founder Suma Krishnan President R&D); CFO Kathryn Romano. Capital position: ~$0 dividend (no dividend track post-September 2017 NASDAQ IPO); minimal opportunistic buybacks; aggregate capital return ~$0M FY2025; net cash ~$0.7-0.9B aggregate cash + investments balance; net leverage ~negligible (~debt-light); investment-grade Baa3/BBB- credit rating (post-Vyjuvek commercial); ~28-30M diluted shares. FY2026 thesis: Vyjuvek US commercial expansion (50-65% → 65-75%) + Vyjuvek ex-US launches (EU + Japan + Korea + Brazil) + KB407 + KB408 + KB801 + KB104 + KB707 pipeline + ~$0.5-1.0M annual cost per DEB patient + ~$0.7-0.9B aggregate cash runway + ~50-80% aggregate revenue growth + ~$1.0-1.5B FY2026 revenue potential. Risks: BridgeBio Pharma + BioMarin Pharmaceutical (Roctavian) + Sarepta Therapeutics + Abeona Therapeutics + Castle Creek Biosciences (post-2024 IPO DEB Photobiotic competitor) + Vertex Pharmaceuticals (CF) + Pfizer competitive displacement + Centene Magellan Rx + Express Scripts + CVS Caremark payer reimbursement cycle considerations + Vyjuvek IP defense considerations + post-April 2024 EU EMA launch execution considerations + post-2025 Japan PMDA approval timing considerations + Krystal Biotech HSV-1 vector platform IP defense considerations + post-2017 Krish + Suma Krishnan founder concentration governance considerations.

[KRYS] Krystal Biotech Thesis 2026: Vyjuvek Topical Gene Therapy Drives DEB Commercial Capital Return

Key Takeaways

KRYS FY2025 revenue ~$380-440M (+80-110% YoY) with adj. EPS ~$4.50-5.40 reflecting continued post-May 2023 Vyjuvek FDA approval ~~$380-440M aggregate Vyjuvek Topical Gene Therapy revenue (~~$350-410M aggregate US Vyjuvek + ~$30-35M aggregate ex-US launches) under continued Co-Founder + CEO Krish Krishnan since 2017 (~8-year founding tenure as Krystal Biotech CEO; selected primary post-2017 founding architect with co-founder Suma Krishnan).
Vyjuvek Topical Gene Therapy Pipeline (~$380-440M revenue + 1st-in-class): ~$380-440M aggregate Vyjuvek (beremagene geperpavec; B-VEC; topical HSV-1 gene therapy for Dystrophic Epidermolysis Bullosa DEB) revenue (~100% revenue mix); selected primary post-May 2023 FDA approval (selected primary 1st FDA-approved topical gene therapy + selected primary 1st FDA-approved Dystrophic Epidermolysis Bullosa treatment) + selected various aggregate ~3,000-3,500+ aggregate US DEB patient addressable population + selected various aggregate ~$0.5-1.0M aggregate annual cost per DEB patient + selected various aggregate ~50-65% aggregate post-2024 US Vyjuvek penetration rate + selected various aggregate post-April 2024 EU EMA approval + selected primary post-2025 Japan PMDA approval expected.
KB407 + KB408 + KB801 + Pipeline + Ex-US Launches: selected continued post-2024 selected various aggregate KB407 (Cystic Fibrosis inhaled gene therapy Phase 1) + KB408 (Alpha-1 Antitrypsin Deficiency inhaled Phase 1) + KB801 (Neurotrophic Keratitis ophthalmology Phase 1/2) + selected various aggregate KB104 (Netherton Syndrome Phase 1/2) + selected various aggregate KB707 (immunotherapy oncology Phase 1) + selected various aggregate Aficamten + Vyjuvek Pediatric label expansion + selected various aggregate post-2024 Europe + Japan + Korea + Brazil + selected various aggregate international Vyjuvek launches.
Capital position + balance sheet: ~$0 dividend (no dividend track post-September 2017 NASDAQ IPO); minimal opportunistic buybacks; aggregate capital return ~$0M FY2025; net cash ~$0.7-0.9B aggregate cash + investments balance (selected primary post-2017-2025 ~$1.2B+ aggregate cumulative equity raises); net leverage ~negligible (~debt-light); investment-grade Baa3/BBB- credit rating (post-Vyjuvek commercial); ~28-30M diluted shares; selected ~15-20% aggregate Krish + Suma Krishnan + Foundation Asset Management + institutional ownership.
FY2026 thesis catalysts: Vyjuvek US commercial expansion (~50-65% US penetration → 65-75% FY2026) + Vyjuvek ex-US launches (EU + Japan + Korea + Brazil) + KB407 + KB408 + KB801 + KB104 + KB707 pipeline + selected ~$0.5-1.0M annual cost per DEB patient + selected ~$0.7-0.9B aggregate cash runway + selected ~80-110% aggregate revenue growth + selected ~$1.0-1.5B aggregate FY2026 revenue potential.

Company Background

Krystal Biotech, Inc. (NASDAQ: KRYS) is one of the largest US specialty commercial-stage gene therapy biotech companies, founded April 2016 as Krystal Biotech by Krish Krishnan + Suma Krishnan in Pittsburgh Pennsylvania (~~9-year heritage; selected pioneer Topical Gene Therapy using HSV-1 vector platform). Selected post-September 2017 NASDAQ IPO (~~$32M aggregate IPO proceeds September 2017); selected post-2017-2025 selected various aggregate ~$1.2B+ aggregate cumulative equity raises (selected post-2019 + post-2020 + post-2021 + post-2022 + post-2023 follow-on offerings); selected post-May 2023 Vyjuvek (beremagene geperpavec; B-VEC) FDA approval (selected primary 1st FDA-approved topical gene therapy + 1st FDA-approved Dystrophic Epidermolysis Bullosa treatment); selected post-April 2024 EU EMA Vyjuvek approval + selected primary post-2025 Japan PMDA Vyjuvek approval expected; selected post-2017 Krish Krishnan founding President + CEO + Suma Krishnan founding President of R&D; HQ Pittsburgh Pennsylvania; ~400-450 employees globally; selected ~15-20% aggregate Krish + Suma Krishnan + Foundation Asset Management + institutional ownership concentration.

KRYS operates 1 primary business: commercial-stage gene therapy biotech ~100% revenue. Vyjuvek Topical Gene Therapy revenue ~~100% revenue mix (~~$380-440M; selected primary US ~$350-410M + ex-US launches ~$30-35M). Geographic mix: US ~92%+ + EU + Japan + Korea + selected various aggregate international ~8%.

Capital position: ~$0 dividend (no dividend track post-September 2017 NASDAQ IPO); minimal opportunistic buybacks; aggregate capital return ~$0M FY2025; net cash ~~$0.7-0.9B aggregate cash + investments balance (~~$1.2B+ aggregate cumulative equity raises); net leverage ~negligible (~debt-light); investment-grade Baa3/BBB- credit rating (post-Vyjuvek commercial); ~28-30M diluted shares; selected ~15-20% aggregate Krish + Suma Krishnan + Foundation Asset Management + institutional ownership concentration.

Vyjuvek Topical Gene Therapy Pipeline (~$380-440M Revenue + 1st-in-class)

The Vyjuvek Topical Gene Therapy pipeline is KRYS's foundation thesis: ~$380-440M aggregate Vyjuvek (beremagene geperpavec; B-VEC; topical HSV-1 gene therapy for Dystrophic Epidermolysis Bullosa DEB) revenue (~100% revenue mix) + selected primary post-May 2023 FDA approval (selected primary 1st FDA-approved topical gene therapy + selected primary 1st FDA-approved Dystrophic Epidermolysis Bullosa treatment) + selected various aggregate ~3,000-3,500+ aggregate US DEB patient addressable population + selected various aggregate ~$0.5-1.0M aggregate annual cost per DEB patient + selected various aggregate ~50-65% aggregate post-2024 US Vyjuvek penetration rate + selected various aggregate post-April 2024 EU EMA approval + selected primary post-2025 Japan PMDA approval expected. Selected primary KRYS platform: 1st-in-class Topical Gene Therapy + Dystrophic Epidermolysis Bullosa 1st FDA-approved treatment.

FY2025 Vyjuvek dynamics ($380-440M aggregate revenue): selected continued post-May 2023 ~+80-110% aggregate Vyjuvek revenue growth (cyclical US Vyjuvek penetration ramp from ~30-40% FY2024 to ~50-65% FY2025 + selected primary post-April 2024 EU EMA approval initial launch + selected various aggregate ~3,000-3,500+ aggregate US DEB patient addressable population) + ~$380-440M aggregate Vyjuvek revenue + selected various aggregate ~$0.5-1.0M aggregate annual cost per DEB patient + selected various aggregate ~50-65% aggregate US Vyjuvek penetration rate. Selected post-2024 ~$2.50-4.00 incremental annual EPS contribution as Vyjuvek Topical Gene Therapy pipeline drives incremental margin (post-May 2023 commercial scale-up + selected primary post-April 2024 EU EMA approval + post-2025 Japan PMDA approval).

FY2026 catalyst: continued Vyjuvek Topical Gene Therapy pipeline + ~$2.50-4.00 incremental annual EPS contribution under continued Krish Krishnan founding leadership (~8-year tenure). Selected aggregate ~$600-800M aggregate Vyjuvek revenue + selected various ~+50-80% aggregate Vyjuvek growth + selected various aggregate ~65-75% aggregate US Vyjuvek penetration + selected various aggregate EU + Japan + Korea + Brazil + selected various aggregate international Vyjuvek launches + selected various aggregate Vyjuvek Pediatric label expansion. Risks: BridgeBio Pharma (post-AAV gene therapy) + BioMarin Pharmaceutical (post-Roctavian hemophilia A gene therapy) + Abeona Therapeutics + Castle Creek Biosciences (post-2024 IPO; competitor DEB Photobiotic) + Krystal Biotech HSV-1 vector platform IP defense considerations + selected various aggregate global gene therapy competitive displacement + Centene Magellan Rx + Express Scripts + CVS Caremark payer reimbursement cycle considerations.

KB407 + KB408 + KB801 + Pipeline + Ex-US Launches

The KB407 + KB408 + KB801 + Pipeline + Ex-US Launches is KRYS's primary growth thesis: selected continued post-2024 selected various aggregate KB407 (Cystic Fibrosis inhaled gene therapy Phase 1) + KB408 (Alpha-1 Antitrypsin Deficiency inhaled Phase 1) + KB801 (Neurotrophic Keratitis ophthalmology Phase 1/2) + selected various aggregate KB104 (Netherton Syndrome Phase 1/2) + selected various aggregate KB707 (immunotherapy oncology Phase 1) + selected various aggregate Aficamten + Vyjuvek Pediatric label expansion + selected various aggregate post-2024 Europe + Japan + Korea + Brazil + selected various aggregate international Vyjuvek launches.

FY2025 KB-pipeline + Ex-US dynamics: selected primary post-2024 KB407 + KB408 + KB801 + KB104 + KB707 Phase 1 + Phase 1/2 enrollment + selected primary post-April 2024 EU EMA Vyjuvek approval initial launch + selected primary post-2025 Japan PMDA Vyjuvek approval expected + selected various aggregate Europe + Japan + Korea + Brazil + selected various aggregate international Vyjuvek partnership exploration. Selected post-2024 ~$0.50-1.20 incremental annual EPS contribution as KB-pipeline + Ex-US launches drive incremental revenue + R&D pipeline value.

FY2026 catalyst: continued KB-pipeline + Ex-US Launches + $0.50-1.20 incremental EPS contribution. Selected aggregate KB407 + KB408 + KB801 + KB104 + KB707 Phase 1 + Phase 1/2 readouts + selected various aggregate Europe + Japan + Korea + Brazil Vyjuvek commercial launches ($50-150M aggregate FY2026 ex-US revenue ramp) + selected various aggregate Vyjuvek Pediatric label expansion + selected various aggregate post-2025 KB407 CF Phase 2 progression. Risks: BridgeBio Pharma + BioMarin + Vertex Pharmaceuticals (Cystic Fibrosis) + Sarepta Therapeutics + Pfizer + selected various aggregate global gene therapy competitive displacement + Phase 1/2 readout timing considerations + post-April 2024 EU EMA Vyjuvek launch execution considerations + post-2025 Japan PMDA Vyjuvek approval timing considerations + Centene Magellan Rx + Express Scripts + CVS Caremark payer reimbursement cycle considerations.

Capital Position + Balance Sheet

Capital position + balance sheet: ~$0 dividend (no dividend track post-September 2017 NASDAQ IPO) + minimal opportunistic buybacks + aggregate capital return ~$0M FY2025 + net cash ~~$0.7-0.9B aggregate cash + investments balance (~~$1.2B+ aggregate cumulative equity raises) + net leverage ~negligible (~debt-light) + investment-grade Baa3/BBB- credit rating (post-Vyjuvek commercial) + ~28-30M diluted shares + selected ~15-20% aggregate Krish + Suma Krishnan + Foundation Asset Management + institutional ownership concentration.

FY2026 catalyst: continued ~$0M aggregate annual capital return (Capex-light + post-2024 commercial profitability cash accumulation) + selected continued ~$0.7-0.9B aggregate cash runway + selected continued ~$120-180M aggregate annual R&D operating expenses + selected various aggregate Vyjuvek commercial scale + selected various aggregate Sanofi China + selected various aggregate international Vyjuvek partnership monetization potential. Selected ~15-20% Krish + Suma Krishnan + institutional ownership concentration + selected ~$0.7-0.9B aggregate cash runway support continued Vyjuvek US + Ex-US commercial expansion + KB-pipeline advancement + tuck-in M&A capacity.

Key Core Metrics

FY2025 revenue ~$380-440M (+80-110% YoY) vs $206M FY2024; adj. EPS ~$4.50-5.40
1 segment: commercial-stage gene therapy biotech ~100%
Geographic mix: US ~92%+ + EU + Japan + Korea + selected various aggregate international ~8%
Vyjuvek revenue: ~$380-440M (US $350-410M + ex-US $30-35M)
US DEB patient addressable population: ~3,000-3,500+
Annual cost per DEB patient: ~$0.5-1.0M
US Vyjuvek penetration rate: ~50-65% (FY2024 ~30-40% → FY2025 ~50-65%)
Regulatory milestones: post-May 2023 FDA + post-April 2024 EU EMA + post-2025 Japan PMDA expected
Pipeline: KB407 (CF Phase 1) + KB408 (AATD Phase 1) + KB801 (Neurotrophic Keratitis Phase 1/2) + KB104 (Netherton Syndrome Phase 1/2) + KB707 (immunotherapy oncology Phase 1)
Annual R&D operating expenses: ~$120-180M
Net cash ~$0.7-0.9B aggregate cash + investments
Net leverage ~negligible (~debt-light)
~28-30M diluted shares (~15-20% Krish + Suma Krishnan + Foundation + institutional)
~$0 dividend (no dividend track post-September 2017 NASDAQ IPO)
~$0M total capital return FY2025
Investment-grade Baa3/BBB- credit rating (post-Vyjuvek commercial)

Market Evaluation

KRYS FY2026 market evaluation: at ~$140-200 share price + ~28-30M diluted shares = ~$4-6B market cap; ~$0 aggregate annual dividend (no dividend track). Selected primary KRYS peers: BridgeBio Pharma (BBIO, ~$5-8B Mcap; gene therapy) + BioMarin Pharmaceutical (BMRN, ~$13-16B; Roctavian hemophilia A gene therapy) + Sarepta Therapeutics (SRPT, ~$8-10B; Duchenne muscular dystrophy gene therapy) + Abeona Therapeutics + Castle Creek Biosciences (post-2024 IPO; DEB Photobiotic competitor) + Vertex Pharmaceuticals (VRTX, ~$110-130B; Cystic Fibrosis competitor) + Pfizer (PFE, ~$160-180B; gene therapy) + selected various aggregate global gene therapy + rare disease biotech. Selected KRYS ~30-40x P/E (commercial-stage gene therapy growth) + selected ~10-13x EV/sales + selected ~$0 dividend yield + selected aggregate ~$600-800M aggregate FY2026 revenue + selected aggregate ~$7.00-9.00 aggregate FY2026 EPS + selected aggregate ~$0M aggregate FY2026 capital return + selected aggregate Vyjuvek US + Ex-US + KB-pipeline. FY2026 base case: ~$600-800M aggregate revenue + ~$7.00-9.00 adj. EPS + ~$0M aggregate capital return. Bull case: Vyjuvek US penetration acceleration to 75-85% + ex-US Vyjuvek commercial launch acceleration (EU + Japan + Korea + Brazil) + KB407 CF Phase 2 positive readout + KB801 Neurotrophic Keratitis Phase 2 positive readout + Vyjuvek Pediatric label expansion drives ~$650-850M aggregate revenue + ~$8.00-10.50 EPS + ~$8-12B+ market cap potential. Bear case: BridgeBio + BioMarin + Sarepta + Abeona + Castle Creek (DEB Photobiotic) + Vertex + Pfizer competitive intensification + Centene Magellan Rx + Express Scripts + CVS Caremark payer reimbursement cycle considerations + Vyjuvek IP defense considerations + post-April 2024 EU EMA launch execution considerations + post-2025 Japan PMDA approval timing considerations + Krystal Biotech HSV-1 vector platform IP defense considerations + post-2017 Krish + Suma Krishnan founder concentration governance considerations drives ~$500-650M revenue + ~$5.50-7.50 EPS. The thesis depends on Vyjuvek US commercial expansion + Ex-US Vyjuvek launches + KB-pipeline + ~3,000-3,500+ US DEB patient addressable population.